The association of interferon with the development of pulmonary tuberculosis

International Journal of Clinical Pharmacology and Therapeutics

Volumn 45, Issue 11, 2007, Pages 598-600

  Farah, Raymond ^a,b   Awad, J ^a  

^a WESTERN GALILEE HOSPITAL   (Israel)

^b NONE   (Israel)

Author keywords

Chronic hepatitis C; Interferon treatment; Tuberculosis

Indexed keywords

ETHAMBUTOL; ISONIAZID; PYRAZINAMIDE; PYRIDOXINE; RECOMBINANT ALPHA2A INTERFERON; RIFAMPICIN;

ACID FAST BACTERIUM; ADULT; ARTICLE; CASE REPORT; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; DISEASE ASSOCIATION; DRUG WITHDRAWAL; HEPATITIS C; HUMAN; HUMAN TISSUE; LIVER BIOPSY; LUNG TUBERCULOSIS; MALE; NUCLEIC ACID AMPLIFICATION; THORAX RADIOGRAPHY; TUBERCULIN TEST;

EID: 35748950741     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/CPP45598     Document Type: Article

References (18)

1. Cooper AM, Pearl JE, Brooks JV, Ehlers S, Orme IM. Expression of the nitric oxide synthase 2 gene is not essential for early control of Mycobacterium tuberculosis in the murine lung. Infect Immun. 2000; 68: 6879-6882.
2. Dalekos GN, Christodoulou D, Kistis KG, Zervou EK, Hatzis J, Tsianos EV. A prospective evaluation of dermatological side-effects during α-interferon therapy for chronic viral hepatitis. Eur J Gastroenterol Hepatol. 1998; 10: 933-939.
3. Davis GL, Balart LA, Schiff ER, Lindsay K, Bodenheimer HC Jr, Perrillo RP, Carey W, Jacobson IM, Payne J, Dienstag JL et al. Treatment of chronic hepatitis C with recombinant interferon-α. A multicenter randomized, controlled trial. Hepatitis Interventional Therapy Group. N Engl J Med. 1989; 321: 1501-1506.
4. Farah R, Farah R, Makhoul N. Interferon-induced pulmonary sarcoidosis. Int J Clin Pharmacol Ther. 2005; 43: 441-443.
5. Giacomini E, Iona E, Ferroni L, Miettinen M, Fattorini L, Orefici G, Julkunen I, Coccia EM. Infection of human macrophages and dendritic cells with Mycobacterium tuberculosis induces a differential cytokine gene expression that modulates T cell response. J Immunol. 2001; 166: 7033-7041.
6. Giosue S, Casarini M, Ameglio F, Zangrilli P, Palla M, Altieri AM, Bisetti A. Aerosolized interferon-α treatment in patients with multidrug-resistant pulmonary tuberculosis. Eur Cytokine Netw. 2000; 11: 99-104.
7. Hoffmann RM, Jung MC, Motz R, Gossl C, Emslander HP, Zachoval R, Pape GR. Sarcoidosis associated with interferon-α therapy for chronic hepatitis C. J Hepatol. 1998; 28: 1058-1063.
8. Maher D, Raviglione M. Global epidemiology of tuberculosis. Clin Chest Med. 2005; 26: 167-182.
9. Nahon P, Brugiere O, Marcellin P, Volla D. Unexpected protective role of interferon-α against Mycobacterium tuberculosis during the course of hepatitis C antiviral therapy. Gastroenterol Clin Biol. 2004; 28: 609-610.
10. Nakajima M, Kubota Y, Miyashita N, Niki Y, Matsushima T, Manabe T. Recurrence of sarcoidosis following interferon-α therapy for chronic hepatitis C. Intern Med. 1996; 35: 376-379.
11. Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, Janecek E, Domecq C, Greenblatt DJ. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981; 30: 239-245.
12. Ramos-Casals M, Mana J, Nardi N, Brito-Zeron P, Xaubet A, Sanchez-Tapias JM, Cervera R, Font J. HISPAMEC Study Group. Sarcoidosis in patients with chronic hepatitis C virus infection: analysis of 68 cases. Medicine. 2005; 84: 69-80.
13. Raviglione MC, O'Brien RJ in: Fauci AS, Braunwald E, Isselbacher KJ et al. Tuberculosis. New York, NY: McGraw-Hill Book Co; Harrison's principles of internal medicine (16th ed). 2005; pp. 953-966.
14. Robinson BW, McLemore TL, Crystal RG. γ-interferon is spontaneously released by alveolar macrophages and lung T lymphocytes in patients with pulmonary sarcoidosis. J Clin Invest. 1985; 75: 1488-1495.
15. Sabbatani S, Manfredi R, Marinacci G, Pavoni M, Cristoni L, Chiodo F. Reactivation of severe, acute pulmonary tuberculosis during treatment with pegylated interferon-α and ribavirin for chronic HCV hepatitis. Scand J Infect Dis. 2006; 38: 205-208.
16. Schneider E, Castro KG. Tuberculosis trends in the United States 1992-2001. Tuberculosis. 2003; 83: 21-29.
17. Warren JR, Bhattacharya M, De Almeida KN, Trakas K, Peterson LR. A minimum 5.0 ml of sputum improves the sensitivity of acid-fast smear for Mycobacterium tuberculosis. Am J Respir Crit Care Med. 2000; 161: 1559-1562.
18. Weiden M, Tanaka N, Qiao Y, Zhao BY, Honda Y, Nakata K, Canova A, Levy DE, Rom WN, Pine R. Differentiation of monocytes to macrophages switches the Mycobacterium tuberculosis effect on HIV-1 replication from stimulation to inhibition: modulation of interferon response and CCAAT/ enhancer binding protein-β expression. J Immunol. 2000; 165: 2028-2039.